title: [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain].
abstract: OBJECTIVE
  To assess the cost-effectiveness of apixaban versus acetylsalicylic acid (ASA) in stroke prevention in patients with non-valvular atrial fibrillation (NVAF) with contraindications of vitamin K antagonists in Spain.
  
  
  METHODS
  A Markov model was adapted, simulating the patient's lifetime. The safety and efficacy of the drugs were obtained from AVERROES clinical trial. The analysis was done from the Spanish National Health System (NHS) and societal perspective. The cost of drugs was calculated according to the recommended doses. The cost of NVAF complications and disease management was obtained from Spanish sources.
  
  
  RESULTS
  In a cohort of 1,000 patients with NVAF, during their lifetime numerous complications could be avoided with apixaban versus ASA (48 ischemic strokes, 10 systemic embolism and 53 related deaths). In each patient treated with apixaban more life-years (0.303 LYG) and more quality-adjusted life-years (0.277 QALYs) could be gained. Apixaban would generate more costs per patient for the NHS (€1,742 per patient) but savings would result from the social perspective (€2,887 saved per patient). The cost per LYG and QALY gained would be of €5,749 and €6,289 for the NHS. Apixaban would be dominant (more effective with less costs than ASA) from the societal perspective. The results were stable in both deterministic and probabilistic sensitivity analyses.
  
  
  CONCLUSIONS
  According to this model, when costs and estimated lifetime outcomes achieved with apixaban are compared with those of ASA, apixaban was assessed to be a cost-effective treatment for the prevention of stroke in patients with NVAF in Spain.
authors.affiliation: Hospital Clínic, Barcelona, España.
authors.forename: Ginés
authors.initials: G
authors.lastname: Escolar-Albaladejo
authors.affiliation: Hospital Universitario Virgen del Rocío, Sevilla, España.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Barón-Esquivias
authors.affiliation: Hospital Universitario Ramón y Cajal, Madrid, España.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Zamorano
authors.affiliation: Departamento de Economía de la Salud, Bristol-Myers Squibb España, Madrid, España.
authors.forename: Lourdes
authors.initials: L
authors.lastname: Betegón-Nicolás
authors.affiliation: Departamento de Economía de la Salud, Bristol-Myers Squibb España, Madrid, España.
authors.forename: Cristina
authors.initials: C
authors.lastname: Canal-Fontcuberta
authors.affiliation: Pfizer España, Madrid, España.
authors.forename: Marina
authors.initials: M
authors.lastname: de Salas-Cansado
authors.affiliation: Health Value, Madrid, España.
authors.forename: Darío
authors.initials: D
authors.lastname: Rubio-Rodríguez
authors.affiliation: Health Value, Madrid, España. Electronic address: crubioterres@healthvalue.org.
authors.forename: Carlos
authors.initials: C
authors.lastname: Rubio-Terrés
mesh_terms: D000368:Aged; D001241:Aspirin / Q000191:economics* / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D011720:Pyrazoles / Q000191:economics* / Q000627:therapeutic use*; D011728:Pyridones / Q000191:economics* / Q000627:therapeutic use*; D013030:Spain; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
chemical_list: D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban; D001241:Aspirin
keywords: Acetylsalicylic acid; Apixaban; Apixabán; Cost-effectiveness; Coste-utilidad; Fibrilación auricular no valvular; Non-valvular atrial fibrillation; Ácido acetilsalicílico
references.citation: Stroke. 2003 Aug;34(8):2060-5
references.pmid: 12843354
references.citation: Pharmacoeconomics. 2006;24(1):81-92
references.pmid: 16445305
references.citation: Stroke. 2001 Sep;32(9):2131-6
references.pmid: 11546907
references.citation: Ann Intern Med. 2011 Jan 4;154(1):1-11
references.pmid: 21041570
references.citation: Ann Intern Med. 2007 Jun 19;146(12):857-67
references.pmid: 17577005
references.citation: Circulation. 2011 Mar 15;123(10):e269-367
references.pmid: 21382897
references.citation: J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):1012-8
references.pmid: 19465412
references.citation: Eur Heart J. 2014 Jul 21;35(28):1897-906
references.pmid: 24513791
references.citation: N Engl J Med. 2011 Mar 3;364(9):806-17
references.pmid: 21309657
references.citation: Eur Heart J. 2007 Oct;28(19):2346-53
references.pmid: 17670754
references.citation: Gac Sanit. 2002 Jul-Aug;16(4):334-43
references.pmid: 12113733
references.citation: Med Decis Making. 2011 Nov-Dec;31(6):800-4
references.pmid: 21422468
references.citation: N Engl J Med. 2011 Sep 15;365(11):981-92
references.pmid: 21870978
references.citation: Rev Esp Cardiol. 2002 Sep;55(9):943-52
references.pmid: 12236924
references.citation: Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):472-9
references.pmid: 22740012
references.citation: Rev Neurol. 2005 Apr 1-15;40(7):406-11
references.pmid: 15849673
references.citation: Arch Intern Med. 1994 Jul 11;154(13):1449-57
references.pmid: 8018000
references.citation: Rev Esp Cardiol (Engl Ed). 2012 Oct;65(10):901-10
references.pmid: 22958943
references.citation: BMC Neurol. 2011 Apr 18;11:46
references.pmid: 21496356
references.citation: Cerebrovasc Dis. 2008;26(4):381-7
references.pmid: 18753743
references.citation: Eur J Neurol. 2007 May;14(5):556-62
references.pmid: 17437616
references.citation: Rev Clin Esp. 2004 Sep;204(9):457-65
references.pmid: 15388019
references.citation: Heart. 2012 Apr;98(7):573-8
references.pmid: 22422743
references.citation: Med Clin (Barc). 2004 Apr 24;122(15):578-83
references.pmid: 15144747
references.citation: Int J Cardiol. 2010 May 14;141(1):18-23
references.pmid: 19144430
references.citation: Circulation. 2011 Jun 7;123(22):2562-70
references.pmid: 21606397
references.citation: J Thromb Haemost. 2008 May;6(5):820-9
references.pmid: 18315548